V Macdonell

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
5127 Background: Neoadjuvant therapy may provide an important paradigm for the discovery of active agents for the therapy of PCa. Bortezomib is a proteasome inhibitor with preclinical activity in PCa. A rationale can be made to study brief preoperative bortezomib before RP to determine feasibility and biologic activity. METHODS A phase II trial was(More)
  • 1